AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$HAE

Haemonetics Q2 Earnings Call Highlights

Haemonetics (HAE) reported 18% organic plasma revenue growth in Q2, raising its full-year apheresis revenue growth forecast. MedSurg revenue grew 6%, and margins improved slightly. The company plans increased capital expenditures for capacity expansion. HAE reaffirmed mid-single-digit MedSurg growth for fiscal 2027, with new product launches in early stages.

Original reporting
finance.yahoo.com
Published Nov 7, 2026, 2:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 7, 2026, 3:14 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Haemonetics Q2 Earnings Call Highlights — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$HAEBullishHigh
01

Why it matters

The earnings beat and guidance raise may support a short‑term rally, but investors should monitor capex spending and margin trends.

02

Market read

First‑time disclosure of earnings and guidance for a niche medical device maker, offering a clear trading catalyst.

03

What to watch

Potential regulatory scrutiny on plasma pricing and competitive pressure from emerging collection technologies.

Relevance 8/10Novelty 8/10Timing: post‑earnings today

Background

Haemonetics reported Q2 results with organic plasma revenue up 18% and raised its full‑year apheresis growth outlook.

Company-level read

Ticker impact

$HAEBullishHigh confidence
Context

Q2 earnings disclosed 18% organic plasma revenue growth and raised full-year apheresis organic revenue growth guidance to high single digits.

Expected impact

likely modest upside as market prices in higher guidance, offset by near‑term capex pressure

Evidence & confidence

First report of earnings numbers and guidance; investors typically reward revenue beat and raised outlook, while noting higher spending.

Market effects

Sector

Strong plasma revenue growth may lift broader blood‑collection equipment sector.

Regional

U.S. collections steady; international growth could benefit global suppliers.

Global

Modest, limited to healthcare technology niche.

Counterpoint

What could challenge this read

Higher capex and modest margin expansion could pressure near‑term earnings, suggesting caution.

Key entities

  • company
    Haemonetics Corporation

    Healthcare technology firm providing blood and plasma collection solutions.

Read at source← All news

Also covered by

1 outlet

Related articles

$HAEMedAI 8/10

Haemonetics Corp (HAE) (Q2 2027) Earnings Call Highlights: Raised Guidance and Expanded

Haemonetics Corp (HAE) reported Q2 2027 earnings, raising guidance but lowering operating margin expansion due to higher costs and investments. CEO Christopher Simon highlighted a multiyear growth opportunity with CSL, though margin contributions are expected in fiscal 2028. The company faces near-term pressures from elevated production and freight costs, with second-half margin expansion weighted toward Q4.

finance.yahoo.com
$HAEHighAI 8/10

Haemonetics Corporation Q2 2027 Earnings Call Summary

Haemonetics reported Q2 2027 plasma growth of 18%, driven by Persona PLUS adoption. CSL relationship expansion and FDA approval for PerQseal Elite were highlighted. Revenue guidance raised to 6-9%, but margin expansion lowered due to supply chain costs. Free cash flow conversion expected to exceed 80%.

finance.yahoo.com
$HAEMedAI 8/10

Haemonetics (HAE) Q2 2027 Earnings Call Transcript

Haemonetics reported Q2 2027 earnings, highlighting 6% organic growth in MedSurg and 14% in Apheresis. Key drivers include TEG 6s disposables, VASCADE products, and Persona PLUS adoption. The company raised its fiscal 2027 revenue guidance to 6%-9% organic growth and 8%-11% reported growth, citing strong first-half performance and increased visibility into customer commitments.

finance.yahoo.com
$HAEMed

Mizuho raises Haemonetics stock price target on plasma strength

Mizuho raised its price target for Haemonetics (HAE) to $165 from $140, citing 18% organic plasma growth and improved guidance. The stock has gained 151% over the past year. HAE reported Q2 earnings of $1.35 per share, beating estimates, with revenue up 9.3% YoY. BTIG also raised its target to $142. Investors note margin guidance concerns and growth spending.

investing.com
$HAEHighAI 8/10

BTIG raises Haemonetics stock price target to $142 on earnings beat

BTIG raised its price target on Haemonetics (HAE) to $142 from $130, maintaining a Buy rating. HAE's Q2 2027 revenue was $357.8M, up 9.3% YoY, beating estimates. Adjusted EPS was $1.35, exceeding expectations. All segments performed well, with Apheresis revenue at $204.8M. Adjusted gross margin increased to 61.9%. HAE raised fiscal 2027 revenue guidance but reduced adjusted EBIT margin expansion outlook.

investing.com